10 August 2015 - PHARMAC is seeking information from suppliers of novel direct-acting antiviral agents (DAAs) for the treatment of hepatitis C.

This Request for Information (RFI) also seeks information from clinicians, hepatitis C healthcare professionals, others who provide support for people with hepatitis C, and those people who are affected by hepatitis C on the services that are provided for people with hepatitis C and the resourcing required for these services.

Examples of the classes of DAAs that PHARMAC is particularly interested in include:

• non-structural protein (NS) 3/4A protease inhibitors
• NS5A inhibitors
• NS5B nucleoside polymerase inhibitors
• NS5B non-nucleoside polymerase inhibitors.

PHARMAC welcomes information relating to other classes of agents available or in development to treat hepatitis C, including but not limited to cyclophilin inhibitors.

PHARMAC is particularly interested in receiving information in relation to those agents, including those in phase II & phase III clinical trials that do not need to be used in combination with pegylated interferon.

Information provided will help inform and assist PHARMAC in determining the most appropriate approach to assessing and making decisions about funding for novel DAAs.

For more details, go to: http://www.pharmac.health.nz/news/rfi-2015-08-10-hepatitis-c-treatments/